Guo-Hong Ge1, Yun Ye1, Xin-Bei Zhou1, Li Chen1, Cong He1, Dan-Feng Wen1, You-Wen Tan1. 1. Guo-Hong Ge, Yun Ye, Xin-Bei Zhou, Li Chen, Cong He, Dan-Feng Wen, You-Wen Tan, Department of Hepatosis, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang 212000, Jiangsu Province, China.
Abstract
AIM: To investigate the virological relapse rate in hepatitis B e antigen (HBeAg)-negative patients after antiviral therapy discontinuation and analyze the factors associated with virological relapse. METHODS: Among patients diagnosed with chronic hepatitis B infection between May 2005 and July 2010, 204 were eligible for analysis. The Kaplan-Meier method and log-rank test were used to calculate the cumulative rate of relapse and compare cumulative relapse rates between groups. The Cox proportional hazards regression model was used to evaluate the predictive factor of virological relapse. RESULTS: The 2 and 1 year cumulative risks of virological relapse after antiviral therapy discontinuation were 79.41% (162/204) and 43.82% (71/162), respectively. Multivariate analysis revealed that only post treatment hepatitis B surface antigen (HBsAg) level was associated with virological relapse (P = 0.011). The cumulative risk of virological relapse was higher in the patients with HBsAg levels ≥ 1500 IU/L than in those with HBsAg levels < 1500 IU/L (P = 0.0013). The area under the curve was 0.603 (P = 0.033). The cutoff HBsAg value for predicting virological relapse was 1443 IU/L. CONCLUSION: We found that the virological relapse rate remained high after antiviral therapy discontinuation in the HBeAg-negative patients and that the post treatment HBsAg levels predicted virological relapse.
AIM: To investigate the virological relapse rate in hepatitis B e antigen (HBeAg)-negative patients after antiviral therapy discontinuation and analyze the factors associated with virological relapse. METHODS: Among patients diagnosed with chronic hepatitis B infection between May 2005 and July 2010, 204 were eligible for analysis. The Kaplan-Meier method and log-rank test were used to calculate the cumulative rate of relapse and compare cumulative relapse rates between groups. The Cox proportional hazards regression model was used to evaluate the predictive factor of virological relapse. RESULTS: The 2 and 1 year cumulative risks of virological relapse after antiviral therapy discontinuation were 79.41% (162/204) and 43.82% (71/162), respectively. Multivariate analysis revealed that only post treatment hepatitis B surface antigen (HBsAg) level was associated with virological relapse (P = 0.011). The cumulative risk of virological relapse was higher in the patients with HBsAg levels ≥ 1500 IU/L than in those with HBsAg levels < 1500 IU/L (P = 0.0013). The area under the curve was 0.603 (P = 0.033). The cutoff HBsAg value for predicting virological relapse was 1443 IU/L. CONCLUSION: We found that the virological relapse rate remained high after antiviral therapy discontinuation in the HBeAg-negative patients and that the post treatment HBsAg levels predicted virological relapse.
Entities:
Keywords:
Chronic hepatitis B; Hepatitis B surface antigen; Virological relapse
Authors: H Fontaine; S Kahi; C Chazallon; M Bourgine; A Varaut; C Buffet; O Godon; J F Meritet; Y Saïdi; M L Michel; D Scott-Algara; J P Aboulker; S Pol Journal: Gut Date: 2014-02-20 Impact factor: 23.059
Authors: Joseph J Y Sung; Deepak Amarapurkar; Henry L Y Chan; Jun Cheng; Jia-Horng Kao; Kwang-Hyub Han; Teerha Piratvisuth Journal: Antivir Ther Date: 2010
Authors: Feng Liu; Lei Wang; Xiao Ying Li; You De Liu; Jing Bo Wang; Zhao Hua Zhang; Yao Zong Wang Journal: J Gastroenterol Hepatol Date: 2011-03 Impact factor: 4.029
Authors: Hyung Rae Sohn; Bo Young Min; Joon Chang Song; Mun Hyuk Seong; Sang Soo Lee; Eun Sun Jang; Cheol Min Shin; Young Soo Park; Jin-Hyeok Hwang; Sook-Hyang Jeong; Nayoung Kim; Dong Ho Lee; Jin-Wook Kim Journal: BMC Infect Dis Date: 2014-08-13 Impact factor: 3.090